Oragenics Reports $4.7 Million Net Loss and Increased R&D Expenses for First Half of 2026

Oragenics, Inc. reported a net loss of $4.7 million for the six months ended June 30, 2026, compared to a loss of $4.5 million for the same period in 2025, reflecting a 5.4% increase in losses year-over-year. The company's total operating expenses rose to $4.8 million, up 29.6% from $3.7 million in the prior year, primarily driven by a significant increase in research and development (R&D) costs, which surged by 130.3% to $1.8 million. General and administrative expenses also saw a modest increase of 2.6%, totaling $3 million for the first half of 2026.

In terms of financial position, Oragenics reported total assets of $5.5 million as of June 30, 2026, a decrease from $10.1 million at the end of 2025. This decline was largely attributed to a reduction in cash and cash equivalents, which fell to $3.9 million from $4.4 million. The company's accumulated deficit increased to $231.4 million, highlighting ongoing challenges in achieving profitability. The total liabilities stood at $1.8 million, slightly up from $1.6 million at the end of the previous fiscal year.

Strategically, Oragenics is focused on advancing its lead product candidate, ONP-002, which is in Phase IIa clinical trials in Australia for the treatment of mild traumatic brain injury (mTBI). The company has enrolled nine participants and administered 34 doses of the study drug. The ongoing clinical trial is expected to support future U.S. trials, with an Investigational New Drug (IND) application targeted for submission by the end of 2026. Additionally, the company has paused negotiations for a potential licensing agreement with Sigyn Therapeutics to focus on its ONP-002 program and capital raising efforts.

Operationally, the company has seen a significant increase in R&D expenses due to higher external professional and consulting costs associated with the ONP-002 program. The increase in cash used in operating activities for the first half of 2026 was $4.4 million, compared to $3.4 million in the same period of 2025. The company also reported a net cash inflow of $4 million from investing activities, primarily from the maturity of a short-term certificate of deposit.

Looking ahead, Oragenics acknowledges the need for additional capital to support its ongoing operations and development activities. The company plans to pursue various financing options, including equity and debt financing, to mitigate liquidity risks. However, there remains substantial doubt about its ability to continue as a going concern without securing sufficient funding. The company’s future capital requirements will depend on the success of its R&D efforts and the progress of its clinical trials, particularly for ONP-002.